GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 8 [WO2016138479] | CT179
Compound class:
Synthetic organic
Comment: CT-179 is a brain-penetrant, orally bioavailable OLIG2 (oligodendrocyte transcription factor 2) inhibitor. It has shown efficacy in targeting OLIG2+ve medulloblastoma stem cells in vitro and in vivo [2-3]. It is one of the OLIG2 inhibitor compounds claimed in Curtana Pharmaceuticals patent WO2016138479A1 [1].
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Beaton G, Tucci FC, Ravula SB, Mchardy SF, Ruiz FX, Lopez A Jr., Campos B, Wang HYL. (2016)
Inhibition of olig2 activity. Patent number: WO2016138479A1. Assignee: Curtana Pharmaceuticals Inc. Priority date: 26/02/2016. Publication date: 01/09/2016. |
|
2. Li Y, Lim C, Dismuke T, Malawsky DS, Oasa S, Bruce ZC, Offenhäuser C, Baumgartner U, D'Souza RCJ, Edwards SL et al.. (2025)
Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179. Nat Commun, 16 (1): 1091. [PMID:39904981] |
|
3. Xu Z, Murad N, Malawsky D, Tao R, Rivero-Hinojosa S, Holdhof D, Schüller U, Zhang P, Lazarski C, Rood BR et al.. (2022)
OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma. Clin Cancer Res, 28 (19): 4278-4291. [PMID:35736214] |